Opus Genetics, Inc. (IRD)
IRD Stock Price Chart
Explore Opus Genetics, Inc. interactive price chart. Choose custom timeframes to analyze IRD price movements and trends.
IRD Company Profile
Discover essential business fundamentals and corporate details for Opus Genetics, Inc. (IRD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jan 2015
Employees
18.00
Website
https://opusgtx.comCEO
George Magrath
Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD Financial Timeline
Browse a chronological timeline of Opus Genetics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.14.
Earnings released on 13 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.25 by +52.00%, while revenue for the quarter reached $2.88M , missing expectations by -15.13%.
Earnings released on 15 May 2025
EPS came in at -$0.32 surpassing the estimated -$0.34 by +5.88%, while revenue for the quarter reached $4.37M , beating expectations by +28.53%.
Earnings released on 31 Mar 2025
EPS came in at -$1.27 falling short of the estimated -$0.34 by -273.53%, while revenue for the quarter reached $4.30M , beating expectations by +26.96%.
Earnings released on 12 Nov 2024
EPS came in at -$0.29 surpassing the estimated -$0.30 by +3.33%, while revenue for the quarter reached $3.87M , missing expectations by -65.18%.
Earnings released on 13 Aug 2024
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%, while revenue for the quarter reached $1.11M , missing expectations by -54.67%.
Earnings released on 10 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.18 by -61.11%, while revenue for the quarter reached $1.71M , missing expectations by -67.96%.
Earnings released on 9 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.05 by -315.20%, while revenue for the quarter reached $1.69M , missing expectations by -68.43%.
Earnings released on 13 Nov 2023
EPS came in at $0.25 surpassing the estimated -$0.22 by +211.80%, while revenue for the quarter reached $11.94M , beating expectations by +294.52%.
Earnings released on 30 Jun 2023
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.73%, while revenue for the quarter reached $3.67M , beating expectations by +51.50%.
Earnings released on 31 Mar 2023
EPS came in at -$0.28 falling short of the estimated -$0.15 by -79.58%, while revenue for the quarter reached $1.75M , missing expectations by -40.74%.
Earnings released on 31 Dec 2022
EPS came in at $1.58 , while revenue for the quarter reached $39.85M .
Earnings released on 30 Sept 2022
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.62%.
Earnings released on 30 Jun 2022
EPS came in at -$0.25 .
Earnings released on 31 Mar 2022
EPS came in at -$0.35 .
Earnings released on 31 Dec 2021
EPS came in at -$0.35 .
Earnings released on 30 Sept 2021
EPS came in at -$0.25 , while revenue for the quarter reached $489.00K .
Earnings released on 30 Jun 2021
EPS came in at -$0.52 , while revenue for the quarter reached $100.00K .
Earnings released on 31 Mar 2021
EPS came in at -$3.57 .
Earnings released on 31 Dec 2020
EPS came in at -$2.40 .
Stock split effective on 6 Nov 2020
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2020
EPS came in at -$0.18 .
IRD Stock Performance
Access detailed IRD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.